SEC Form 4 · accession 0001192591-26-000004
Maze Therapeutics, Inc. · MAZE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles J Homcy
Director
Period of report
Jun 8, 2026
Accepted (ET)
Jun 10, 2026 · 4:25 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001842295
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $23.58 | Jun 8, 2026 | A | 18,000 | A | — | Jun 7, 2036 | Common Stock | 18,000 | 18,000 | D |
Explanation of responses
- F1The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.